Evidence map›Paper›PMID 36097232›Full record

ArticleAnnals of nuclear medicine2022

[

Sajad Kaihani, Nourollah Sadeghzadeh, Saeid Abediankenari, Seyed Mohammad Abedi

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sajad KaihaniDepartment of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, 48471-93698, Mazandaran, Iran.
Nourollah SadeghzadehDepartment of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, 48471-93698, Mazandaran, Iran. nsadeghzadeh@mazums.ac.ir.
Saeid AbediankenariImmunogenetics Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Seyed Mohammad AbediDepartment of Radiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mazandaran University of Medical Sciences · IR

Funding

Mazandaran University of Medical Sciences 6301
6 · The paper itself

Abstract

purposeIn this study, we designed a new linear 6-Hydrazinonicotinamide (HYNIC)-conjugated peptide (HYNIC-KRWrNM) (M-6) and labeled with technetium-99m for gamma imaging of glioblastoma as a α PROCEDURES: One new linear peptide (HYNIC-KRWrNM) (M-6) was designed and labeled with technetium-99m in the presence of 2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl] amino] acetic acid (Tricine)/Ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligand system. Then, this

resultsThe radiochemical yield of [

conclusionsThis small linear

Indexed as

GlioblastomaOrganotechnetium CompoundsAnimalsCell Line, TumorEthylenediaminesHumansIntegrin alphaVbeta3Integrin beta3LigandsMiceMice, NudeNaphtholsOligopeptidesPeptidesSaline SolutionTechnetium5,6-dihydroxy-2-dimethylaminotetralinEthylenediaminesIntegrin alphaVbeta3Integrin beta3LigandsNaphtholsOligopeptidesOrganotechnetium CompoundsPeptidesSaline SolutionTechnetium99mTcCyclic RGD peptidesHYNIC-KRWrNMLinear peptideαvβ3 integrin

Identifiers

PMID36097232
OpenAlexW4295485967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.